Generic Name and Formulations:
Lipase/protease/amylase: 3000Units/9500Units/15000Units; 6000Units/19000Units/30000Units; 12000Units/38000Units/60000Units; 24000Units/76000Units/120000Units; 36000Units/114000Units/180000Units; del-rel caps containing e-c spheres.
Indications for CREON:
Treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
Adults and Children:
See literature. Start at the lowest recommended dose and increase gradually. Individualize based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet. Infants: May sprinkle directly into mouth or into a small amount of applesauce; do not mix directly into formula or breastmilk. ≤12months: 3000 lipase units per 120mL of formula or per breastfeeding. Children and adults: Do not crush or chew caps; swallow whole, or may open and sprinkle contents into small amount of acidic food (pH≤4) and swallow mixture immediately. >12months–<4yrs: 1000 lipase units/kg per meal; ≥4yrs: 500 lipase units/kg per meal. Max (for children and adults): 2500 lipase units/kg per meal (or ≤10000 lipase units/kg per day), or <4000 lipase units/g fat ingested per day. Adults with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy: individualize; in one study, patients received 72,000 lipase units per meal while consuming 100g of fat per day; lower starting doses are consistent with the 500 lipase units/kg per meal lowest starting dose recommended for adults in the guidelines.
Not interchangeable with any other pancrelipase products. Pork allergy. Potential viral transmission. Gout. Renal impairment. Hyperuricemia. Contents irritating to mucosa. Pregnancy (Cat.C). Nursing mothers.
Pancreatic enzymes (porcine).
Abdominal pain, abnormal feces, cough, dizziness, flatulence, headache, weight decreased; hyperuricemia, fibrosing colonopathy (with high doses), allergic reactions.
Caps 3000—70; 6000, 12000, 24000, 36000—100, 250
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States